Cases
Add toChapter 11 data in the AI you already use
BioXcel, renamed BX Liquidation, Inc. on November 16 Dkt. 339, has closed its court-approved sale to Teva for $57.5 million in cash plus up to $67.5 million in FDA- and sales-linked milestones allsci.com: Teva swoops for BioXcel neuroscience assets in bankruptcy sale for up to USD 125m ahead of FDA decision (outside source). At a hearing set for December 3, 2026, the debtors will ask Judge Horan to confirm their liquidating plan, which sends the sale value to the secured lenders, over the general unsecured class's rejection Dkt. 331.
| Week | Entries |
|---|---|
| Week of Aug 24, 2026 | 46 |
| Week of Aug 31, 2026 | 46 |
| Week of Sep 7, 2026 | 6 |
| Week of Sep 14, 2026 | 33 |
| Week of Sep 21, 2026 | 47 |
| Week of Sep 28, 2026 | 41 |
| Week of Oct 5, 2026 | 14 |
| Week of Oct 12, 2026 | 17 |
| Week of Oct 19, 2026 | 36 |
| Week of Oct 26, 2026 | 22 |
| Week of Nov 2, 2026 | 18 |
| Week of Nov 9, 2026 | 10 |
| Week of Nov 16, 2026 | 14 |
Case facts and filing dates come from court records.Case docket on PACER